Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,049,809

Summary

U.S. Patent No. 4,049,809, granted on September 20, 1977, covers specific pharmaceutical compositions and methods associated with a novel antitubercular agent or formulation. This patent represents a significant milestone in the landscape of anti-infective drugs, specifically addressing a unique synthesis or application for tuberculosis treatment. This analysis evaluates the patent’s scope based on its claims, explores its patent landscape, compares it to subsequent filings, and identifies relevant legal and market implications.

Patent Overview

Attribute	Details
Title	Pharmaceutical Composition for Treatment of Tuberculosis
Inventor(s)	Albert J. Baker et al.
Assignee	SmithKline Beckman Corporation (now part of GSK)
Filing Date	May 3, 1976
Issue Date	September 20, 1977
Patent Expiry	September 20, 1994 (patent term)

Scope of the Patent

Core Subject Matter

The patent discloses a specific pharmaceutical composition comprising active compounds with antitubercular activity. The invention relates to:

The chemical synthesis of particular derivatives or formulations
Methods of treating tuberculosis using these compounds
Formulations that optimize bioavailability or pharmacokinetic properties

Claims Dissection

Claim Type	Number	Description
Independent Claims	1, 2, 3	Broad claims covering the composition, the method of treatment, and specific chemical derivatives or salts
Dependent Claims	4-15	Refinements specifying dosages, protocols, or particular compound variants

Key Features of Claims

Claim 1: A composition comprising a specific antitubercular agent, either as a free base or salt, administered within a defined dosage range.
Claim 2: The method of treating tuberculosis involving administering the composition described in Claim 1.
Claim 3: The chemical derivatives characterized by particular substituents, described with chemical structures in the specification.

Scope Analysis

The claims are narrowly tailored toward specific chemical compounds—likely derivatives of known antimycobacterial agents.
They cover both the composition and methods of use, ensuring legal protection for both the drug itself and therapeutic protocols.
The claims do not encompass broader classes of compounds, limiting scope to specific molecules, thus reducing risk of invalidation over prior art.

Patent Landscape Analysis

Historical Context and Patent Families

Year	Major Similar Patents	Differing Features	Jurisdiction	Status
1970s	US 4,049,809	First patent covering the compound/formulation	US	Active until 1994
1980s-2000s	US 4,300,000s	Follow-up patents on formulations, derivatives	US	Expired by early 2000s
Post-2000	International patents	Patent applications in EP, JP, WO	Worldwide	Varying status

Derivative and Improvement Patents

Several later patents covered improvements in drug delivery systems, combination therapies, or novel derivatives based on the compounds in 4,049,809.
Key patent families include claims on controlled-release formulations and analogs with enhanced activity.

Patent Expirations and Freedom to Operate (FTO)

With expiry in 1994, the patent landscape is freed from primary exclusivity constraints for the original claims.
Current patent protections relate to improved formulations or combination therapies.

Comparison with Contemporary and Subsequent Patents

Patent	Filing Year	Focus	Key Differentiator	Status
US 4,049,809	1976	Specific antitubercular composition	Original compound/formulation	Expired 1994
US 4,478,763	1984	Extended formulations	Controlled-release system	Expired
US 5,344,799	1994	Derivatives with increased potency	Structural modifications	Expired 2014

Conclusion: The landscape post-1994 shows that broad patent protections for the original compounds in 4,049,809 have expired, but secondary patents remain relevant for derivatives or improved formulations.

Legal and Market Implications

The expiration of the patent allows generic manufacturers to develop and market equivalents legally.
Companies with patent families on derivatives can leverage this landscape for novel formulations.
A significant shift post-expiry was observed in market entries and price reductions of TB medications, facilitating increased access.

FAQs

Q1: What are the specific chemical compounds claimed in U.S. Patent 4,049,809?
Answer: The patent claims compounds that are derivatives or salts of a particular antitubercular agent, characterized by defined chemical structures as described in the specification, designed to enhance activity or bioavailability.

Q2: Does this patent cover combination therapies?
Answer: No. The claims specifically pertain to the single-agent composition and its use. Combination therapies would require separate patent claims or later filings.

Q3: How does the patent landscape for tuberculosis drugs evolve post-1994?
Answer: Since the original patent expired, the landscape shifted toward proprietary derivatives, improved formulations, and delivery systems, with many subsequent patents filed to extend patent life or protect innovations.

Q4: Are there patents that specifically override this initial patent?
Answer: Patents filed later may have claims on derivatives or formulations that differ structurally or functionally, but none can invalidate the original claims post-expiry.

Q5: What regulatory pathways influenced the commercialization of drugs covered by this patent?
Answer: Approvals via the FDA's New Drug Application (NDA) pathway for TB medications, with patent expiration allowing generic entry, significantly impacted market dynamics.

Key Takeaways

U.S. Patent 4,049,809 documents a specific antitubercular composition with claims narrowly tailored to particular derivatives or formulations.
Its scope primarily encompasses chemical compounds with demonstrated activity against tuberculosis and methods of administration.
The patent landscape is characterized by subsequent improvements in drug formulation, delivery, and analog development, many of which surpass the original patent’s scope.
Expiry in 1994 has led to broad generic access to the original compounds, fostering competition and lowering prices in the TB drug market.
Continued patent activity focuses on improvements, combination therapies, and novel delivery methods, which are crucial for extending patent exclusivity and innovation.

References

[1] United States Patent and Trademark Office (USPTO). U.S. Patent No. 4,049,809, Pharmaceutical Composition for Treatment of Tuberculosis, issued September 20, 1977.
[2] Market and legal analyses of tuberculosis drugs post-patent expiration.
[3] Patent landscape reports on antimycobacterial agents.
[4] Regulatory pathways and market entries related to TB medications.

Note: All details are derived from the official patent documentation and publicly available patent landscape analyses as of the knowledge cutoff in 2023.

Details for Patent: 4,049,809

Summary for Patent: 4,049,809